本帖最后由 老马 于 2013-3-13 13:43 编辑 $ W0 x6 D, L, _8 U M b4 R6 v
: U7 G/ H- z" ^$ f* o7 z
健择（吉西他滨）+顺铂+阿瓦斯汀
7 P/ O/ M3 O/ [ Gemzar +Cisplatin + Avastin! ]4 H! Z; K5 @/ ~* N' S; l
http://annonc.oxfordjournals.org/content/21/9/1804.full- O/ C" O {: i# w7 P0 S
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) & j% c9 M$ Z6 b* A: v$ h
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. : P7 a" K' ~9 q- d. h" T
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
9 F" }+ C7 s$ R
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 922)
) J2 |, |; F3 |9 Y. a
华为网盘附件：2 _# S; d# U/ c. }! x6 ~
【华为网盘】ava.JPG
5 b" H6 z$ V. o1 s |
父亲肺鳞癌，cT3N0M1a，ⅣA，脑转移
父亲2025年6月中旬因为头痛，一侧肢体不灵活入院，做了增强核磁，发现右侧额叶占位（3
妈妈化疗的艰难时刻，倍瑞博营养液带
当母亲被确诊为肺腺癌四期的那一刻，我们全家如坠冰窟。随之而来的化疗更是煎熬——
惋惜 关于一位术后2期肺腺癌病友止步
曾经一起抗癌的老病友很多都陆陆续续地抗癌结束了，如今都各自有了新的生活，当
EGFR靶点病人，到底适不适合免疫治疗
一直一直在听说，肺癌EGFR突变的病人，免疫治疗很难获益，甚至有超进展可能，具体哪里
化疗吃不下怎么办？倍瑞搏辅助饮食心
着至亲在化疗的煎熬中一天天消瘦，吃不下、喝不进，那种揪心和无力感，相信很多病友家
显身卡
